Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China.

Diabetes Metab Syndr Obes · 2020 · PMC7431175 · PMID 32848438

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The stability of these results is driven by the importance of reduced main adverse cardiovascular event rates, which were highly significant in the EMPA-REG OUTCOME trial.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.